The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects

Renal Insufficiency Clinical Trial

Official title:

The Pharmacokinetic, Safety and Tolerability of Tiotropium (4.8 mcg, Single i.v. Dose) in Outpatients With Renal Impairment in Comparison to Healthy Subjects (Open Label, Group Comparison, Two-center Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02172339
• Other study ID #: 205.134
• Status: Completed
• Phase: Phase 1
• First received: June 20, 2014
• Last updated: June 20, 2014
• Start date: April 1998

Study information

• Verified date: June 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Study to investigate pharmacokinetics of a single i.v. dose of tiotropium (4.8 mcg) in patients with renal impairment in comparison to healthy subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. primary completion date: December 1998
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Subjects:

1. Subject with normal renal function ( creatinine clearance of 80% of predicted creatinine clearance in healthy volunteers), as confirmed by normal physical examination including vital signs, ECG and laboratory values

Calculated creatinine clearance (male);

= ((140 - age(yr)) x (Wt (kg))) / (72 x predicted serum creatinine (mg/dL))

Calculated creatinine clearance (female);

= ((140 - age(yr)) x (Wt(kg))) / (85 x predicted serum creatinine (mg/dL))

2. Subject with impaired renal function must be of age related good health and without clinically significant abnormalities as assessed during the physical examination. Mildly impaired renal patients were defined as those with creatinine clearance of 40 - 80% of predicted creatinine clearance; moderately impaired renal patients were defined as those with creatinine clearance of 10 - 40% of predicted creatinine clearance. Laboratory values of subjects with renal impairment could have been outside the normal range if the deviations were due to the underlying renal disease.

2. Male or female, age between 40 and 70 years with normal body - weight index (+/- 25%, Broca-index)

3. Subjects with normal 12 - lead ECG recording

4. Subjects with normal physical examination

5. Subjects with normal clinical and laboratory tests (except for indicators of renal impairment)

6. Female of child bearing potential must have a negative pregnancy test

7. All subjects must have a negative HIV-Ab test and negative Hepatitis B test

8. All subjects must have a negative drug screening

9. All subjects must sign a written informed consent prior to enrollment

Exclusion Criteria:

1. Subjects with a history of more then moderate alcohol consumption (more than 1 litre of beer per day or the equivalent amount of alcohol in any other alcoholic beverage, approximately 50 g of alcohol per day). 24 hours before dosing and 24 hours post dosing, alcohol was not permitted

2. Present or past participation in a drug detoxification program

3. Smokers

4. Subjects requiring any concomitant medication not compatible with this study

5. Subjects with hypotension (systolic blood pressure less than 100 mmHg, diastolic less than 60 mmHg) or hypertension (systolic blood pressure more than 165 mmHg or diastolic more than 100 mmHg) under adequate medication

6. Subjects who participated in a clinical trial of any other investigational drug within two months prior to the start of this study

7. Pregnant or lactating women or women of child bearing potential not using a medically approved means contraception. (i.e., oral contraceptives, intrauterine devices, diaphragm)

8. Subjects who donated blood within three months prior to the start of the study

9. Subjects with a history of chronic or recurrent convulsive disorders or ongoing hepatic dysfunction

10. Subjects with ongoing acute systemic illness or recovery from acute systemic illness

11. Subjects with a history of cancer within the last five years

12. Subjects with known hypersensitivity to anticholinergic drugs

13. Subjects with known symptomatic prostatic hypertrophy or bladder neck obstruction

14. Subjects with known narrow-angle glaucoma

Study Design

Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Renal Insufficiency

Intervention

Drug:
• Tiotropium, solution ampoules

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve (AUC (0-4h) of plasma levels of tiotropium after dosing)		pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration	No
Primary	Renal clearance of tiotropium (CLren )		Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1	No
Primary	Terminal half-life of tiotropium		pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration	No
Primary	Urinary excretion (0-4h) of tiotropium, Ae 0-4h		Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1	No
Secondary	Change from baseline in Pulse Rate (PR)		baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25	No
Secondary	Change from baseline in Blood pressure (BP)		baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25	No
Secondary	Number of Participants with Serious and Non-Serious Adverse Events		up to day 25	No
Secondary	Change from baseline in electrocardiogram (ECG)		baseline, day 1, 2, 7, 15 and 25	No
Secondary	Maximum measured concentration of the analyte in plasma (Cmax )		pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration	No
Secondary	Time from dosing to the maximum concentration of the analyte in plasma (tmax)		pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration	No
Secondary	Change in FEV1 (Forced expiratory volume in one second)		baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25	No
Secondary	Change in FVC (Forced vital capacity)		baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25	No

External Links

•   Link